《大行報告》大和升瑞聲(02018.HK)評級至「跑贏大市」 目標價上調至51元
大和發表研究報告,指瑞聲(02018.HK)似乎已渡過最困難時期,目前正待復甦之時,公司首季業績表現強勁,反映其執行能力和提供盈利復甦的證明,故將其評級由「持有」升至「跑贏大市」,該行調升集團2021至22年盈利預測10%至12%,目標價由43.5元升至51元。
該行指,看好集團光學和安卓業務的前景,而來自蘋果的業務則較穩定,相信盈利會於今年起有強勁復甦。受惠集團規模效益及營運效率持續改善,預期今明年經營利潤率由去年谷底的7.9%,回復至12.1%至13.4%,整體而言,今明兩年盈利料按年增62%及28%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.